Gelati M, Corsini E, Dufour A, Ciusani E, Massa G, Frigerio S, Milanese C, Nespolo A, Salmaggi A
Istituto Nazionale Neurologico C. Besta, Milan, Italy.
Acta Neurol Scand. 1997 Nov;96(5):283-92. doi: 10.1111/j.1600-0404.1997.tb00285.x.
Methylprednisolone (MP) is a synthetic steroid commonly used in the treatment of multiple sclerosis (MS) relapses. It has a wide spectrum of activities on immune cells: it might also act by preventing mononuclear cell/endothelium adhesion. We studied adhesion phenomena between cultured human umbilical vein endothelial cells (HUVECs) and PBMNCs (CD45+, CD14+) from 6 MS patients treated in vivo with MP. We also studied fluctuations in CD11a and CD18 levels on lymphocytes and monocytes, as well as changes in serum sICAM-1 and sVCAM-1 concentrations. After MP treatment, PBMNCs adhesion to endothelium decreased at 3 h, while it went back to baseline levels at 24 h. A tendency to increase in both CD11a and CD18 on the surface of lymphocytes was detected, while an increase in serum sVCAM-1 was seen at 3 h.
甲基泼尼松龙（MP）是一种常用于治疗多发性硬化症（MS）复发的合成类固醇。它对免疫细胞具有广泛的活性：它也可能通过阻止单核细胞/内皮细胞粘附起作用。我们研究了用MP进行体内治疗的6例MS患者的培养人脐静脉内皮细胞（HUVEC）与外周血单核细胞（PBMNC，CD45 +，CD14 +）之间的粘附现象。我们还研究了淋巴细胞和单核细胞上CD11a和CD18水平的波动，以及血清可溶性细胞间粘附分子-1（sICAM-1）和可溶性血管细胞粘附分子-1（sVCAM-1）浓度的变化。MP治疗后，PBMNC与内皮细胞的粘附在3小时时降低，而在24小时时恢复到基线水平。检测到淋巴细胞表面的CD11a和CD18均有增加的趋势，而血清sVCAM-1在3小时时升高。
